MedTrace Logo

Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses

NCT00167843 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1189

Last updated 2013-01-24

No results posted yet for this study

Summary

The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.

Conditions

Interventions

DRUG

sulfadoxine-pyrimethamine

Sponsors & Collaborators

  • Medical Research Unit, Lambarene

    collaborator UNKNOWN

  • Bundesministerium fuer Bildung und Forschung (BMBF)

    collaborator UNKNOWN

  • Deutscher Akademischer Austausch Dienst

    collaborator OTHER

  • German Research Foundation

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Albert Schweitzer Hospital

    lead OTHER

Principal Investigators

  • Peter G Kremsner, MD · Albert Schweitzer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
5 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-12-31
Completion
2007-03-31

Countries

  • Gabon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167843 on ClinicalTrials.gov